×

Randomized trial of botulinum toxin to prevent pes cavus progression in pediatric charcot-marie-tooth disease type 1A: Burns J et al.

Musscle Nerve  42: 262–267, 2010
JOSHUA BURNS, PhD, 1,2
ADAM SCHEINBERG, MMed, 3,4
MONIQUE M. RYAN, MMed, 5
KRISTY J. ROSE, MHSc, 2
and ROBERT A. OUVRIER, MD, 2
Faculty of Health Sciences, University of Sydney, Sydney, New South Wales, Australia 
Institute for Neuroscience and Muscle Research, Children’s Hospital at Westmead, Locked Bag 4001, Sydney,New South Wales 2145, Australia 
Department of Rehabilitation, The Children’s Hospital at Westmead, Sydney, New South Wales, Australia 
 Victorian Paediatric Rehabilitation Service, Victoria, Australia 
Children’s Neuroscience Centre, Royal Children’s Hospital/Murdoch Children’s Research Institute/Department of Paediatrics,Faculty of Medicine, University of Melbourne, Victoria, Australia

Bitte hier klicken!

Botulinum toxin type A in the treatment of lower-limb spasticity in children with cerebral palsy: Camargo CHF et al.

Arq Neuropsiquiatr 2009;67(1):62-68
Carlos Henrique F. Camargo
Hélio A.G. Teive
Marise Zonta
Gilmar C. Silva
Marcelo R. Oliveira
Maurício M. Roriz
Ivar V. Brandi
Nilson Becker 
Rosana Hermínia Scola
Lineu César Werneck 

Bitte hier klicken!

The management of spastic equinus in cerebral palsy: Cobeljic G et al.

2009, Orthopaedics and Trauma 23:3
Goran Cobeljic
Marko Bumbasirevic
Aleksandar Lesic
Zoran Bajin

Bitte hier klicken!

A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force: Albanese A M et al.

European Journal of Neurology  2006,  13: 433–444
Membership: A. Albanese (chairman) a,
M. P. Barnes  b, 
K. P. Bhatia  c,
E. Fernandez-Alvarez  d,
G. Filippini  a,
T. Gasser   e,
J. K. Krauss  f,
A. Newton  g,
I. Rektor  h,
M. Savoiardo  a,
J. Valls-Solei
a
Istituto Nazionale Neurologico Carlo Besta, Milan, Italy;
 b
Hunters Moor Regional Rehabilitation Centre, Newcastle Upon Tyne, UK;
c
Institute of Neurology, University College London, Queen Square, London, UK;
 d
Neuropediatric Department, Hospital San Joan de Dieu,Barcelona, Spain;
 e
Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research, University of Tu ¨ bingen,Germany;
 f 
Department of Neurosurgery, Medical University of Hanover, MHH, Hannover, Germany;
 g
European Dystonia Federation,Brussels, Belgium;
 h
First Department of Neurology, Masaryk University, St. Anne’s Teaching Hospital, Brno, Czech Republic; and 
i
Neurology Department, Hospital Clı´ nic, Barcelona, Spain

Bitte hier klicken!

High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy: Willis AW et al.

Dev Med Child Neurol. 2007 November ; 49(11): 818-822. doi:10.1111/j.1469-8749.2007.00818.x.
Allison W Willis, MD, Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Beth Crowner, MS, PT, Program in Physical Therapy, Washington University School of Medicine, St Louis, MO, USA
Janice E Brunstrom, MD, Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Abigail Kissel, BA, and Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
Brad A Racette, MD *Department of Neurology, Washington University School of Medicine, St Louis, MO, US

Split-Screen Video Demonstration of Sonography-Guided Muscle Identification and Injection of Botulinum Toxin: Fietzek U M et al.

Movement Disorders
Vol. 25, No. 13, 2010, pp. 2225–2252
2010 Movement Disorder Society
Urban M. Fietzek, MD, 1
A. Sebastian Schroeder, MD, 2
Joerg Wissel, MD, PhD, 3
Florian Heinen, MD, PhD, 2
and Steffen Berweck, MD, PhD 2,4 *
1
 Neurologisches Krankenhaus Mu¨ nchen, Center for  Parkinson’s Disease and Movement Disorders, Mu¨ nchen, Germany;
 2
 Department of Pediatric Neurology and Developmental Medicine, Dr. von Hauners’ Children’s Hospital, Ludwig-Maximilians-University Munich, Mu¨ nchen,Germany;
 3
 Neurologische Rehabilitationsklinik, Beelitz-Heilsta¨ tten, Beelitz-Heilsta¨ tten, Germany;
 4
Treatment Centre Vogtareuth, Specialist Centre for  Neuropediatric Rehabilitation, Vogtareuth, Germany

Bitte hier klicken!

Low Prevalence of Botulinum Toxin-A Adverse Effects: Good Safety Profile or Underreporting?: Aimer O et al.

2017 Journal of Novel Physiotherapy andPhysical Rehabilitation ISSN: 2455-5487
O.Aimer  *
N.Roche 2,
3
H.Michelon 1
A.Schnitzler 4,5
K.Hamami 1
L.Fellous 1
F.Genet 3,4
M.Villart 1
1
Service de pharmacie, Hôpital Raymond Poincaré,APHP, 104 bd Raymond Poincaré, 92380 Garches,France
2
Service de neurophysiologie, Hôpital RaymondPoincaré, APHP, 104 bd Raymond Poincaré, 92380Garches, France
3
Université Versailles Saint Quentin en Yvelines, «End:icap » U1179 INSERM, UFR des Sciences de laSanté – Simone Veil, France
4
Service de Médecine Physique et de Réadaptation,Hôpital Raymond Poincaré, APHP, CIC-IT1429, 104bd Raymond Poincaré, 92380 Garches, France
5
Université Versailles Saint Quentin en Yvelines,HANDI-ReSP (EA4047), UFR des Sciences de laSanté – Simone Veil France

Bitte hier klicken!

Systemic Adverse Events Following Botulinum Toxin A Therapy in Children with Cerebral Palsy: Naidu K et al.

2010, Developmental Medicine & Child Neurology
KRISHANT NAIDU 1,2
 
KATHERINE SMITH 2
 
MARY SHEEDY 1
 
BROOKE ADAIR 1
 
XAVIER YU  
H KERR GRAHAM 1,2,3
1
 The Royal Children’s Hospital, Melbourne, Victoria, Australia.
 2
 Murdoch Childrens Research Institute, Melbourne, Victoria, Australia.
 3
 The University of Melbourne,Melbourne, Victoria, Australia.
Correspondence to Professor H Kerr Graham at the Orthopaedic Department, The Royal Children’s Hospital, Flemington Road, Parkville, Victoria 3052, Australia. E-mail: kerr.graham@rch.org.au

Bitte hier klicken!

International Neurology – A Clinical Approach: Editors R P LISAK et al.

2009, A Clinical Approach

This edition first published 2009, ©2009 by Blackwell Publishing Ltd
EDITED BY
ROBERT P. LISAK MD FAAN FRCP
Parker Webber Chair in NeurologyProfessor and Chair of NeurologyProfessor of Immunology and MicrobiologyWayne State University School of Medicine;Neurologist-in-Chief, Detroit Medical CenterChief of Neurology, Harper University HospitalDetroit, MI, USA
DANIEL D. TRUONG MD FAAN
Head of The Parkinson and Movement Disorder InstituteMemorial Neuroscience InstituteOrange Coast Memorial Medical CenterFountain Valley, CA, USA
WILLIAM M. CARROLL MBBS MD FRACP FRCP(E)
Head of Neurology and Clinical NeurophysiologySir Charles Gairdner HospitalNedlands, Perth, Australia
ROONGROJ BHIDAYASIRI  MD FRCP
DirectorChulalongkorn Comprehensive Movement Disorders CenterChulalongkorn University HospitalBangkok, Thailand;University of California at Los AngelesLos Angeles, CA, USA
FOREWORD BY JOHN WALTON (LORD WALTON OF DETCHANT

Bitte hier klicken!

Treatments for spasticity and pain in multiple sclerosis: a systematic review: Beard S et al.

Health Technol Assess 2003; 7 (40).
S Beard, A Hunn, J Wight
School of Health and Related Research (ScHARR),University of Sheffield, UK

Bitte hier klicken!

Botulinum Toxin Type a for Upper Limb Spasticity Following Stroke: An Open-Label Study With Individualised, Flexible Injection Regimens: Slawek J et al.

Neurol Sci (2005) 26:32–39
DOI 10.1007/s10072-005-0379-8
J. Slawek, A. Bogucki, D. Reclawowicz

Bitte hier klicken!

Best Clinical Practice in Botulinum Toxin Treatment for Children with Cerebral Palsy: Strobl W et al.

Toxins 2015, 1629-1648; doi:10.3390/toxins7051629
ISSN 2072-6651
www.mdpi.com/journal/toxins
Walter Strobl1,†, Tim Theologis2, Reinald Brunner3, Serdar Kocer4, Elke Viehweger5,Ignacio Pascual-Pascual6 and Richard Placzek7,†,*
1
 Department of Paediatric- and Neuro-Orthopaedics, Orthopaedic Hospital Rummelsberg,90592 Schwarzenbruck, Germany and MOTIO, 1080 Vienna, Austria;E-Mail: walter.strobl@sana.de
2
 Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, Windmill Road Headington, Oxford OX3 7LD, Oxfordshire, UK;E-Mail: timtheologis@googlemail.com
3
Department of Paediatric- and Neuro-Orthopaedics, University Children’s Hospital Basel (UKBB),Spitalstrasse 33, 4056 Basel, Switzerland; E-Mail: reinald.brunner@ukbb.ch
4
Centre de Réadaptation de COUBERT (Ugecam) 77170, France and ROMATEM,Etiler Istanbul 34337, Turkey; E-Mail: skocer1@gmail.com
5
Pediatric Orthopaedics and Institue of Motion Sciences Department, Aix-Marseille Université,Boulevard Jean Moulin, Marseille 13885, France; E-Mail: elke.viehweger@mail.ap-hm.fr
6
Department of Paediatrics, Hospital Infantil La Paz, Universidad Autonóma de Madrid, Madrid,Spain; E-Mail: sipascual@telefonica.net
7
Orthopedic Department, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany
These authors contributed equally to this work.
 
* Author to whom correspondence should be addressed; E-Mail: richard.placzek@ukb.uni-bonn.de;Tel.: +49-0228-287-14170; Fax: +49-0228-287-14175.Academic Editor: Bahman Jabbari

Bitte hier klicken!